Neurosteroids in pain management: A new perspective on an old player by Joksimovic, Sonja L et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2018
Neurosteroids in pain management: A new
perspective on an old player
Sonja L. Joksimovic
University of Colorado, Denver
Douglas F. Covey
Washington University School of Medicine in St. Louis
Vesna Jevtovic-Todorovic
University of Colorado, Denver
Slobodan M. Todorovic
University of Colorado, Denver
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Joksimovic, Sonja L.; Covey, Douglas F.; Jevtovic-Todorovic, Vesna; and Todorovic, Slobodan M., ,"Neurosteroids in pain
management: A new perspective on an old player." Frontiers in Pharmacology.9,. 1127. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7288
fphar-09-01127 September 29, 2018 Time: 16:41 # 1
REVIEW
published: 02 October 2018
doi: 10.3389/fphar.2018.01127
Edited by:
Sonja Maksim Vuckovic,
University of Belgrade, Serbia
Reviewed by:
Nebojsa Nick Knezevic,
Advocate Illinois Masonic Medical
Center, United States
Ioannis N. Charalampopoulos,
University of Crete, Greece
*Correspondence:
Sonja L. Joksimovic
sonja.joksimovic@ucdenver.edu
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 27 July 2018
Accepted: 14 September 2018
Published: 02 October 2018
Citation:
Joksimovic SL, Covey DF,
Jevtovic-Todorovic V and
Todorovic SM (2018) Neurosteroids
in Pain Management: A New
Perspective on an Old Player.
Front. Pharmacol. 9:1127.
doi: 10.3389/fphar.2018.01127
Neurosteroids in Pain Management:
A New Perspective on an Old Player
Sonja L. Joksimovic1* , Douglas F. Covey2,3, Vesna Jevtovic-Todorovic1 and
Slobodan M. Todorovic1,4
1 Department of Anesthesiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States,
2 Department of Developmental Biology, School of Medicine, Washington University in St. Louis, St. Louis, MO,
United States, 3 Taylor Family Institute for Innovative Psychiatric Research, School of Medicine, Washington University in
St. Louis, St. Louis, MO, United States, 4 Neuroscience Graduate Program, University of Colorado Denver, Anschutz
Medical Campus, Aurora, CO, United States
Since the discovery of the nervous system’s ability to produce steroid hormones,
numerous studies have demonstrated their importance in modulating neuronal
excitability. These central effects are mostly mediated through different ligand-gated
receptor systems such as GABAA and NMDA, as well as voltage-dependent Ca2+
or K+ channels. Because these targets are also implicated in transmission of sensory
information, it is not surprising that numerous studies have shown the analgesic
properties of neurosteroids in various pain models. Physiological (nociceptive) pain has
protective value for an organism by promoting survival in life-threatening conditions.
However, more prolonged pain that results from dysfunction of nerves (neuropathic
pain), and persists even after tissue injury has resolved, is one of the main reasons
that patients seek medical attention. This review will focus mostly on the analgesic
perspective of neurosteroids and their synthetic 5α and 5β analogs in nociceptive and
neuropathic pain conditions.
Keywords: neurosteroids, chronic pain, T-channel (CaV3), T-channel calcium channel blockers, neurosteroid
analogs, analgesic (activity)
INTRODUCTION
Since the discovery of steroid hormone synthesis in the rat nervous system (Corpechot et al., 1981),
numerous studies have shown the pivotal role of steroid hormones in various neuronal functions,
such as cognition, memory, affective disorders, neuroprotection, and myelination (Schumacher
et al., 2012, 2014; Brinton, 2013; Giatti et al., 2015). These molecules are called neurosteroids,
because they are produced in the nervous system by neurons and/or glial cells (Baulieu and
Robel, 1990). Today, all steroid hormones that exert an effect on inhibitory and excitatory
neurotransmission, regardless of their mechanism(s) and source (whether they are synthetic or
endogenously produced), are considered neuroactive steroids (Paul and Purdy, 1992).
Neurosteroids are capable of modulating cell function on different levels. Conventionally,
their effects are attributable to specific nuclear hormone receptors (e.g., progesterone)
that regulate RNA expression. The onset of such effects is much slower, but the
consequential changes may be long lasting. On the other hand, neurosteroids also exert their
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effects in the nervous system through modulation of various
receptor systems and ionic channels (Baulieu et al., 1999;
Mensah-Nyagan et al., 1999; Mellon and Griffin, 2002; Belelli
and Lambert, 2005). Some of them, such as GABAA and
NMDA receptors and/or voltage-dependent T-type Ca2+ or
voltage-dependent K+ channels, are heavily implicated in sensory
pathways responsible for mediating anesthesia and analgesia.
The present review focuses on the role of neurosteroids in pain
pathways, their potential as analgesics in different pain models,
and future therapeutic perspectives.
THE ROLE OF NEUROSTEROIDS IN PAIN
PATHWAYS
The International Association for the Study of Pain (IASP)
defines pain as “an unpleasant sensory and emotional experience
associated with actual or potential tissue damage, or described
in terms of such damage.” Although acute nociceptive pain has
protective value for an organism, promoting survival in life-
threatening conditions (Basbaum et al., 2009), prolonged pain
that persists even after tissue injury has resolved is one of the
main reasons that patients seek medical attention (Costigan et al.,
2009).
Some of the first studies with intravenously injected
cholesterol showed that steroid molecules could suppress painful
information and decrease arousal by exerting an anesthetic-
like state in mammals (Cashin and Moravek, 1927). In
this study, abdominal surgery on cats was performed after
intravenous (IV) administration of cholesterol, and animals
were fully recovered. The pregnane class of steroids has
become particularly important because of their allosteric
modulation of neuronal GABAA receptors. Brot et al. (1997)
showed that allopregnanolone mediates its anxiolytic effect
by stimulating chloride flux through the channel of GABAA
receptors via either binding sites different from the one
for benzodiazepines, or via sites allosterically linked to the
picrotoxin binding site. More recent studies have shown
that neurosteroids are influencing the kinetics of synaptic
GABAA-gated ion channels by prolonging the decay time of
phasic responses, and therefore enhancing neuronal inhibition
(Belelli and Lambert, 2005; Herd et al., 2007). Furthermore,
neurosteroids also exert their effects via extrasynaptic GABAA
receptors containing the δ-subunit, thus enabling tonic inhibition
(Lambert et al., 2001). This effect was confirmed in a
study of Stell et al. (2003) where tonic conductance was
significantly reduced in mice lacking the δ-subunit of GABAA
receptors, and was not influenced by 5α-pregnan-3α,21-diol-
20-one (3α,5α-tetrahydrodeoxycorticosterone,3α,5α-THDOC), a
potent stereoselective positive allosteric modulator of the GABAA
receptor. The anxiolytic and anesthetic effects of 3α,5α-THDOC
were attenuated in these mice (Mihalek et al., 1999). Altogether,
these findings could explain the ability of neurosteroids to induce
sedation and anesthesia in rodents.
Numerous clinical and animal studies have found that
sex hormones can differentially regulate pain perception.
For example, testosterone exerts analgesic effect in both
humans and animal models, while estrogen can act both
as an analgesic and hyperalgesic (Aloisi, 2003; Ceccarelli
et al., 2003; Aloisi et al., 2004; Arendt-Nielsen et al., 2004;
Aloisi and Bonifazi, 2006). It is well known that fluctuations
of estrogen and progesterone during the estrous cycle can
influence pain perception and pain threshold (Frye et al.,
1992, 1993; Riley et al., 1998; Kuba and Quinones-Jenab,
2005). Furthermore, it seems that estrogen and progesterone
may regulate the antinociceptive conformation of mu and
kappa opioid receptor heterodimers (Chakrabarti et al.,
2010), which makes them immensely important in pain
regulation.
Several studies have confirmed the existence of particular
enzymes involved in steroidogenesis throughout the central
nervous system (CNS) and peripheral nervous system (PNS)
(for review Baulieu and Robel, 1990; Compagnone and Mellon,
2000; Mensah-Nyagan et al., 2009). These compounds are crucial
for plasticity of the nervous system (Patte-Mensah et al., 2006;
Melcangi et al., 2008); therefore, they also play a very important
role in pain perception and pain modulation. Interestingly,
extensive studies on the dorsal horn region of the spinal cord
have not been conducted. However, it is well known that the
dorsal horn of the spinal cord plays a pivotal role in the
transmission of painful stimuli from the peripheral nociceptors
to supraspinal structures. It is also well established that primary
afferent fibers coming from peripheral nociceptive neurons,
whose cell bodies lie in the dorsal root ganglia (DRG), form
synapses with the projection neurons of the dorsal horn of
the spinal cord. These neurons further convey information to
the brainstem, thalamic, and cortical structures (Millan, 1999,
2002) that are able to modulate nociceptive transmission via
several descending pathways at the level of the spinal cord.
Because modulation of pain perception occurs at the level of
dorsal horn neurons in the spinal cord, it is not surprising
that a particular set of enzymes, including a CYP450, involved
in steroidogenesis was identified (Patte-Mensah et al., 2004;
Mensah-Nyagan et al., 2008). An immunohistochemical study
by Patte-Mensah et al. (2003) has confirmed that the highest
density of these enzymes was detected in superficial layers of
laminae I and II, where the first synapses between the nociceptive
peripheral sensory neurons and projection neurons are located.
Furthermore, homogenates of the rat spinal cord were capable
of converting cholesterol into progesterone confirming that the
enzymes are indeed functional. Locally synthetized progesterone
in the spinal cord has also been shown to stimulate intrinsic
spinal anti-nociceptive system via kappa and delta opioid
receptors and promoting the increase of endorphins in situ
(Dawson-Basoa and Gintzler, 1997, 1998). Additionally, there
is evidence of direct inhibition of allopregnanolone synthesis
in the dorsal horn with substance P, a potent pronociceptive
neuropeptide (Patte-Mensah et al., 2005). This finding indicates
that the presence of neuroactive steroids at the level of the
dorsal horn could regulate GABA inhibitory tone, and that
the pronociceptive effect of substance P released from primary
afferents could be due to the reduction of GABAA receptor
activity by downregulating the production of 3α, 5α-THP
(allopregnanolone). These data strongly suggest that there
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FIGURE 1 | Neurosteroid synthesis in the spinal cord from cholesterol.
is an active process of neurosteroid synthesis in the dorsal
horn, particularly progesterone and allopregnanolone (two very
potent analgesic neurosteroids) by direct enzymatic conversion
(Figure 1).
ENDOGENOUS NEUROSTEROIDS AND
PAIN
Recent studies suggest that progesterone and its derivatives,
dihydroprogesterone (DHP) and 3α, 5α-tetrahydroprogesterone
(THP) or allopregnanolone, have a specific neuroprotective
action in the central and PNS (Guennoun et al., 2008, 2015;
Melcangi et al., 2014; Schumacher et al., 2014). For example,
these molecules are capable of exerting beneficial effects in
pathological conditions such as traumatic brain injury and
spinal cord injury by promoting myelination and preserving
white matter. In addition, endogenous neurosteroids show
positive therapeutic effect in conditions such as Alzheimer’s
and Parkinson’s disease (Irwin et al., 2014; Schumacher
et al., 2014). Allopregnanolone, in particular, has been shown
to promote neurogenesis by increasing neural progenitor
proliferation of subgranular zone of dentate gyrus in adult
3xTgAD mice. Furthermore, in the same mouse model of
Alzheimer’s disease, allopregnanolone reversed the conditioned
response/associative learning deficits of 3xTgAD mice to a level
comparable to non-Tg mice (Wang et al., 2010). Furthermore, in
allopregnanolone treated 3xTgAD mice, a significant reduction
of β-amyloid production was noticeable (Chen et al., 2011).
Allopregnanolone increased dopamine release from nucleus
accumbens in freely moving rats (Rougé-Pont et al., 2002)
and improved motor performance by promoting neurogenesis
of tyrosine hydroxylase immunoreactive neurons is substantia
nigra (Adeosun et al., 2012) in the mouse model of Parkinson’s
disease.
Numerous studies have also shown that steroids modulate
pain sensitivity, either through intracellular/nuclear targets, or by
modulation of synaptic transmission, both directly and indirectly
via second-messenger systems. Potentiation of inhibitory GABA-
ergic transmission in the pain pathway is one of the important
mechanisms to diminish pain transmission (Zeilhofer et al.,
2013). Predictably, analgesic potential of neuroactive steroids
that promote GABA-mediated transmission in different pain
paradigms is very well established.
Several other mechanisms are involved in analgesia induced
by neurosteroids. It has been shown that progesterone, applied
subcutaneously, successfully alleviated both mechanical and
thermal allodynia in the sciatic nerve injury model, by preventing
injury-induced increase of NR-1 subunit of NMDA receptors,
as well as expression of PKCγ (Coronel et al., 2011). This
reduction of PKCγ prevents the phosphorylation of NR1 subunit
of NMDA receptors, which is crucial for receptor facilitation
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and contributes to the development of central sensitization.
Antiallodynic effect of progesterone was also achieved in the
spinal cord injury pain model (Coronel et al., 2014). The
authors have shown that application of progesterone significantly
reduced spinal expression of COX-2 and iNOS after spinal
cord injury, revealing an anti-inflammatory activity of this
endogenous neurosteroid that could contribute to its analgesic
properties. Furthermore, the existence of receptors in dorsal
horn neurons, sensitive to progesterone, supports the notion
of the importance of neurosteroid induced modulation of pain
processing (Labombarda et al., 2010). A particular type of
receptor, sigma-1 receptor, a chaperone residing in endoplasmic
reticulum, has recently been investigated as a potential target
for progesterone binding in the spinal cord (Maurice et al.,
2006; Monnet and Maurice, 2006; de la Puente et al., 2009).
Sigma-1 receptors chaperon proper folding of nascent proteins.
However, in certain conditions, such as binding of agonists,
they could translocate to the cell membrane and interact
with different G-protein coupled receptors and ionic channels.
Previous studies have confirmed the presence of sigma-1 receptor
in the dorsal horn neurons (de la Puente et al., 2009), as well
as on DRG (Mavlyutov et al., 2016) which implicates them in
the development of neuropathic pain and spinal sensitization
after nerve injury. It has also been shown that activation of
sigma-1 receptors leads to increased activity of PKC and PKA,
which in turn induces phosphorylation of NR1 subunit of NMDA
receptors, a process highly implicated in the development of
central sensitization (Kim et al., 2008). Ortíz-Rentería et al. (2018)
discovered that blocking sigma-1 receptors by progesterone leads
to a significant decrease of TRPV1-dependent pain produced by
capsaicin. Different authors have shown that treatment of sciatic
nerve constriction and orofacial pain models with progesterone
also successfully reduced mechanical and thermal allodynia
(Dableh and Henry, 2011; Kim et al., 2012).
Of particular interest is dehydroepiandrosterone (DHEA), one
of the first discovered neurosteroids (Baulieu et al., 1999). DHEA
is found to be converted from pregnenolone by cytochrome
P450c17 in the CNS. Although it can be found in human plasma,
in rodents, plasma levels are extremely low, most likely since
cytochrome P450c17 does not exist in rodent adrenals. However,
DHEA synthesis exists in the spinal cord (Kibaly et al., 2005), a
pivotal part of the sensory pathways, important for nociceptive
transmission. Therefore, the importance of DHEA in modulation
of pain perception should be considered. Kibaly et al. (2007)
have found that when injected either peripherally (subcutaneous)
or centrally (intrathecal), DHEA exerts pronociceptive effects by
reducing the pain thresholds to painful stimuli. However, the
repeated injections of DHEA exert a sustained analgesic effect.
This indicates that DHEA exerts its acute algogenic effects most
likely via either direct allosteric modulation of NMDA or P2X
receptors, or via sigma-1 receptors, which in turn enhances
phosphorylation of NR1 subunit of NMDA receptors (Yoon
et al., 2010), leading to increased sensitization of pain pathways.
On the other hand, delayed analgesic effect of DHEA could be
explained by its metabolism to androgens in the spinal cord, such
as testosterone, that exert analgesic effects (Kibaly et al., 2007).
Dehydroepiandrosterone seems to possess another feature,
related to neuroprotection. A recent study of Lazaridis et al.
(2011) indicated that DHEA prevented neuronal apoptosis by
interacting with transmembrane tyrosine kinase receptor TrkA.
TrkA receptors are a known group of target receptors for the
nerve growth factor (NGF). Via these receptors, NGF prevents
cell apoptosis. Thus, the authors have discovered that, by binding
to TrkA, DHEA exerts an antiapoptotic effect in HEK-293 cells,
and reversal of apoptotic loss of TrkA positive sensory neurons in
DRG of NGF null mouse embryos.
On the other hand, NGF/TrkA signaling pathway has already
been implicated in pain transmission (Hirose et al., 2016). From
the developmental standpoint, NGF is necessary during fetal
period for normal growth of sensory nerve fibers belonging
to pain pathways. However, during the adulthood, an NGF
increase occurs during peripheral inflammation and nerve injury.
This increase of peripheral NGF leads to the sensitization of
surrounding nerves inducing pain, which is a protective response
to prevent further tissue injury. But, if the inflammation and
nociception persist, the protective value of increased NGF is lost
leading to central and peripheral sensitization of pain pathways,
and to the development of chronic pain states. This notion
has been confirmed in the study by Ashraf et al. (2016) where
an experimental compound has been utilized to antagonize
effects of NGF via blocking the TrkA receptors, and therefore
reducing pain and joint damage in rat models of inflammatory
arthritis. Interestingly, a synthetic analog of DHEA, named
BNN27, has been recently shown to interact with TrkA receptors
(Pediaditakis et al., 2016) on DRG neurons without exerting
pronociceptive behavior. This indicates a selective action against
neurodegeneration but not influencing the pain pathways.
Therefore, the rogue neurosteroid DHEA, and synthetic analogs,
could have a more pleiotropic role, by simultaneously interacting
with different receptor systems and hence, exerting different
effects, that could be both beneficial and detrimental, depending
on the activated pathways, age, and pathologies. Further studies
are needed to elucidate the mechanisms of these dichotomous
effects of DHEA in the pain pathway.
Progesterone’s metabolites, DHP and THP, have also been
proven to act as analgesics in various pain models. For example,
in the sciatic nerve crush injury model, progesterone and DHP
successfully alleviated thermal nociception. This is possibly
accomplished by restoring the thickness of the myelin and
reducing the density of the fibers, as well as normalizing the
function of Na+/K+-ATPase pump activity (Roglio et al., 2008).
In chemically induced neuropathies, such as streptozotocin-
induced diabetic neuropathy and chemotherapy-induced
neuropathy, progesterone, allopregnanolone, and 5α-DHP
have alleviated either thermal and/or mechanical nociception
(Leonelli et al., 2007; Meyer et al., 2010, 2011).
Pathirathna et al. (2005b) have shown that allopregnanolone
successfully alleviated mechanical and thermal hyperalgesia in
the neuropathic pain model of loose sciatic nerve ligation
in rats by modulating both T-type Ca2+ channels (T-
channels) and GABAA receptors. Specifically, allopregnanolone
was a more potent analgesic than its analogs, which
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FIGURE 2 | Proposed mechanisms of analgesic effect of endogenous and synthetic neurosteroids.
only inhibited T-channels or potentiated GABAA-gated
currents.
Additionally, Ayoola et al. (2014) have found that local
paw injections of epipregnanolone, an endogenous 5β-reduced
neurosteroid without potentiating effects at GABAA receptors,
successfully alleviated mechanical and thermal sensitivity in both
wild-type mice and rats, but not in CaV3.2 T-type calcium
channel knock-out mice. This suggests that the antinociceptive
effect of epipregnanolone is mediated largely by inhibition of
T-channels in peripheral nociceptors.
Taken together, these data strongly suggest that endogenously
produced neuroactive steroids are very potent analgesics in
different pain models, and that they exert their analgesic effects
via various receptor systems and ion channels, most notably
GABAA receptors and T-type calcium channels (Figure 2).
On one hand, their ability to evoke effects through different
receptor systems, either directly or through second-messenger
systems, makes them an excellent alternative to conventional
therapeutic options for treating various pain states. On the
other hand, drugs that target so many receptor systems
often produce various adverse events in humans. Therefore,
creating a potent, but more selective, neuroactive steroid
would be a focus of future studies of these interesting
compounds.
ANALGESIC PROPERTIES OF 5α- AND
5β-REDUCED STEROID ANALOGS
The role of GABAA receptors as the main inhibitory receptors
in pain pathways is well established (Millan, 1999); however,
the role of voltage-gated Ca2+ channels (VGCCs) has not
been explored as thoroughly. Based upon the membrane
potential that activates them, VGCCs can be divided into
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two categories: high-voltage-activated (HVA) and low-voltage-
activated T-type Ca2+ channels. Of interest for this review
are T-type Ca2+ channels that are important targets for many
analgesic neurosteroids. Since the discovery of the role of
these channels in neuronal excitability, and their presence
on peripheral sensory neurons whose cell bodies are located
in the DRG (Carbone and Lux, 1984), a growing interest
for studying these channels in pain transmission has arisen
(Todorovic et al., 2001; Bourinet et al., 2005; Jacus et al., 2012;
Rose et al., 2013). Therefore, synthetic analogs of neuroactive
steroids with affinity for T-channels have been synthetized
to investigate their role in both acute and chronic pain
models.
Among several synthetic 5α-analogs tested, our previous
work has shown that ECN, [(3β,5α,17β)-17-hydroxyestrane-3-
carbonitrile], a potent enantioselective blocker of T-channels
without potentiating effects at GABAA receptors (Todorovic
et al., 1998), induced potent analgesia when applied locally as an
intraplantar injection in healthy rats (Pathirathna et al., 2005a).
Furthermore, when combined with CDNC24, a GABAA selective
neurosteroid without analgesic effect per se, the antinociceptive
effect of ECN was greatly potentiated. This synergistic analgesia
was abolished with a GABAA-receptor antagonist biccuculine,
indicating that there is an interplay between GABAA receptors
and T-channels in peripheral nociceptors that helps them to
work in concert when alleviating acute pain (Pathirathna et al.,
2005a).
These two 5α-reduced analogs have been shown to alleviate
pain in chronic neuropathy as well. Our group has shown that
in a model of chronic constrictive injury (CCI) of the sciatic
nerve, local intraplantar injections of either ECN or CDNC24
more selectively alleviated thermal nociception in neuropathic
animals than in a sham group, as compared to allopregnanolone
or alphaxalone (Pathirathna et al., 2005b). This can be explained
by the fact that synthetic neurosteroids are more selective to
either GABAA and/or T-channels, while allopregnanolone and
alphaxalone have many other targets on which to exert their
antinociceptive effect.
The fact that CDNC24 exerted effect in injured but not in
healthy animals can be explained by the changes in expression
and/or conductance of GABAA receptors during injury. The
study of Xiao et al. (2002) has confirmed the increase in mRNA
levels for α5 subunit of GABAA receptors on the cell bodies
of peripheral sensory neurons, while Yang et al. (2004) have
shown the upregulation of α5 subunit of the GABAA receptor
in the spinal cord after nerve injury. It is noteworthy that both
alphaxalone and allopregnanolone may exert antinociceptive
effect through potentiating GABAA currents as well as inhibiting
T-currents. More importantly, after blocking the GABA-ergic
effect with biccuculine, a potent analgesia could still be observed,
indicating that a great portion of neurosteroid-induced analgesic
effect is related to the T-channel inhibition. As previously
mentioned, neuroactive steroids have various targets to prevent
mechanisms that trigger plasticity changes in the nervous
system. Perhaps a future strategy of preventing neuropathic
pain could be achieved by blocking T-channels heavily involved
in neuronal excitability. Furthermore, systemic intraperitoneal
administration of ECN effectively reversed mechanical and
thermal hyperalgesia in painful diabetic neuropathy in morbidly
obese leptin-deficient ob/ob mice (Latham et al., 2009). In
addition, some studies have implicated GABAA receptors in
the dorsal horn of spinal cord as important targets for
treatment of painful diabetic neuropathy (Jolivalt et al., 2008).
These data strongly suggest that neurosteroids targeting either
T-type channels and/or GABAA receptors may be beneficial in
treatment of intractable pain associated with peripheral diabetic
neuropathy.
Recent behavioral and immunohistological studies have
confirmed the presence of both GABAA receptors and the
CaV3.2 isoform of T-channels on the peripheral nociceptors
(Rose et al., 2013; Obradovic et al., 2015). CaV3.2 isoform
of T-channels has also been found presynaptically in the
spinal cord where these channels support glutamate release
from the central endings of nociceptive sensory neurons (Jacus
et al., 2012). In addition, the CaV3.1 isoform of T-channels
controls the opioidergic descending inhibition from the low-
threshold spiking GABAergic neurons in the periaqueductal
gray (PAG; Park et al., 2010). Some previous studies showed
that an increase of intracellular calcium in Purkinje cells
increases sensitivity to GABA (Llano et al., 1991). On the
other hand, intracellular calcium decreases the affinity of GABA
receptors in sensory neurons of the bullfrog (Inoue et al.,
1986). Perhaps, in the PNS, blocking the T-channels leads
to the decreased intracellular Ca2+, which in turn leads to
the increased activity of GABAergic inhibition. Overall, these
data suggest that there is a strong interaction between the
GABAergic inhibitory system and T-type channels in both
central and peripheral components of the pain pathway.
However, exact mechanisms of this interaction remain to be
determined.
Previous work from our lab has also shown that synthetic
5β-reduced neurosteroids can successfully alleviate somatic
pain (Todorovic et al., 2004). The steroid structures tested
both in vitro and in vivo contain either 3-cyano and 17-
hydroxyl groups or 3-hydroxyl and 17-cyano groups. These
selective T-channel blockers have exerted significant and dose-
dependent analgesia when injected locally into the plantar
surface of the hind paw in healthy rats. Specifically, (3β,5β,17β)-
3-hydroxyandrostane-17-carbonitrile (3β-OH) was one of the
most effective synthetic 5β- reduced neurosteroids in alleviating
thermal nociception. Interestingly, the potency to block isolated
T-currents in DRG neurons in vitro corresponded well to their
potency to exert thermal antinociception in vivo. Furthermore,
3β-OH has been recently shown to possess hypnotic effect
and was able to induce loss of righting reflex in neonatal
rats without causing harmful effects to the brain of exposed
animals (Atluri et al., 2018). It is reasonable to assume that
both analgesic and hypnotic effects were likely exerted by
blocking low voltage activated T-channels, suggesting that
this novel synthetic neurosteroid with a specific and selective
mechanism of action could be used for preemptive analgesia
and anesthesia. However, further studies are needed to test
this notion, and to investigate the effects of other synthetic
neurosteroid analogs in both acute and chronic pain models.
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CONCLUSION
Endogenous neurosteroids are very potent molecules with
effects on many crucial processes in the nervous system. By
targeting several different receptor systems, they are able to
reduce maladaptive changes in the sensory nervous system,
which in turn could prevent the development of central
sensitization and chronic pain states. Perhaps, increasing the
production of endogenous neurosteroids, such as progesterone
and allopregnanolone, in the spinal cord and peripheral nerves
would be a future therapeutic option for treating various pain
states in humans. This strategy has already been employed in
several animal studies and has proven successful in neuropathic,
inflammatory, as well as in postoperative pain models (Aouad
et al., 2009; Giatti et al., 2009; Hernstadt et al., 2009; Mitro
et al., 2012; Xiong et al., 2017). By targeting specific translocator
protein-18 kDa (TSPO) and/or liver X receptors (LXR), it is
possible to increase neuronal steroidogenesis, thus preventing
systemic endocrine effects that could appear as a consequence of
systemic application of neurosteroids.
On the other hand, synthetic 5α- and 5β-reduced steroid
analogs have great potential in treating acute and chronic pain.
Since rigid steroid molecules can be sculpted to generate more
selective compounds towards GABAA receptors and T-channels,
they may be the most interesting in terms of further development
as novel pain therapies. An example would be 3β-OH, a synthetic
neurosteroid with hypnotic and analgesic properties, that could
be a promising new agent to reduce postsurgical hyperalgesia,
when applied as a part of a balanced anesthesia, thus potentially
reducing the necessity for other analgesic drugs, such as opioids
after surgery. By specifically targeting key ion channels that
contribute to the modulation of pain perception, synthetic
neurosteroids could in turn alleviate pain in patients, hopefully
with less adverse events than currently used therapies. Future
clinical trials are necessary to investigate their analgesic potential
and safety profile in the human population.
AUTHOR CONTRIBUTIONS
SJ wrote the main draft of the manuscript. ST, VJ-T, and DC
revised the draft of the manuscript and made final corrections.
All authors approved the final version of the manuscript.
FUNDING
This work was supported by NIH grant 1 R01 GM123746-01 to
ST and VJ-T, the funds from the Department of Anesthesiology
at UC Denver.
ACKNOWLEDGMENTS
We thank Dr. Tamara Timic Stamenic for providing the drawing
of the spinal cord. SJ created Figure 2.
REFERENCES
Adeosun, S. O., Hou, X., Jiao, Y., Zheng, B., Henry, S., Hill, R., et al. (2012).
Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons
and motor performance in an MPTP-lesioned mouse model of Parkinson’s
disease. PLoS One 7:e50040. doi: 10.1371/journal.pone.0050040
Aloisi, A. M. (2003). Gonadal hormones and sex differences in pain reactivity. Clin.
J. Pain 19, 168–174. doi: 10.1097/00002508-200305000-00004
Aloisi, A. M., and Bonifazi, M. (2006). Sex hormones, central nervous system and
pain. Horm. Behav. 50, 1–7. doi: 10.1016/j.yhbeh.2005.12.002
Aloisi, A. M., Ceccarelli, I., Fiorenzani, P., De Padova, A. M., and Massafra, C.
(2004). Testosterone affects formalin-induced responses differently in male and
female rats. Neurosci. Lett. 361, 262–264. doi: 10.1016/j.neulet.2003.12.023
Aouad, M., Charlet, A., Rodeau, J. L., and Poisbeau, P. (2009). Reduction and
prevention of vincristine-induced neuropathic pain symptoms by the non-
benzodiazepine anxiolytic etifoxine are mediated by 3α-reduced neurosteroids.
Pain 147, 54–59. doi: 10.1016/j.pain.2009.08.001
Arendt-Nielsen, L., Bajaj, P., and Drewes, A. M. (2004). Visceral pain: gender
differences in response to experimental and clinical pain. Eur. J. Pain 8,
465–472. doi: 10.1016/j.ejpain.2004.03.001
Ashraf, S., Bouhana, K. S., Pheneger, J., Andrews, S. W., and Walsh, D. A. (2016).
Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and
joint damage in two rat models of inflammatory arthritis. Arthritis Res. Ther.
18:97. doi: 10.1186/s13075-016-0996-z
Atluri, N., Joksimovic, S. M., Oklopcic, A., Milanovic, D., Klawitter, J., Eggan, P.,
et al. (2018). A neurosteroid analogue with T-type calcium channel blocking
properties is an effective hypnotic, but is not harmful to neonatal rat brain. Br.
J. Anaesth. 120, 768–778. doi: 10.1016/j.bja.2017.12.039
Ayoola, C., Hwang, S. M., Hong, S. J., Rose, K. E., Boyd, C., and Bozic, N.,
et al. (2014). Inhibition of CaV3.2 T-type calcium channels in peripheral
sensory neurons contributes to analgesic properties of epipregnanolone.
Psychopharmacology 231, 3503–15. doi: 10.1007/s00213-014-3588-0
Basbaum, A. I., Bautista, D. M., Scherrer, G., and Julius, D. (2009).
Cellular and molecular mechanisms of pain. Cell 139, 267–284.
doi: 10.1016/j.cell.2009.09.028
Baulieu, E., and Robel, P. (1990). Neurosteroids: a new brain function? J. Steroid
Biochem. Mol. Biol. 37, 395–403. doi: 10.1016/0960-0760(90)90490-C
Baulieu, E. E., Robel, P., and Schumacher, M. (1999). Contemporary Endocrinology.
Neurosteroids: a New Regulatory Function in the Nervous System. Totowa:
Humana Press.
Belelli, D., and Lambert, J. J. (2005). Neurosteroids: endogenous regulators of the
GABA A receptor. Nat. Rev. Neurosci. 6, 565–575. doi: 10.1038/nrn1703
Bourinet, E., Alloui, A., Monteil, A., Barrère, C., Couette, B., Poirot, O., et al.
(2005). Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons
demonstrates its major role in nociception. EMBO J. 24, 315–324. doi: 10.1038/
sj.emboj.7600515
Brinton, R. D. (2013). Neurosteroids as regenerative agents in the brain: therapeutic
implications. Nat. Rev. Endocrinol. 9, 241–250. doi: 10.1038/nrendo.2013.31
Brot, M. D., Akwa, Y., Purdy, R. H., Koob, G. F., and Britton, K. T. (1997). The
anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with
GABA(A) receptors. Eur. J. Pharmacol. 325, 1–7. doi: 10.1016/S0014-2999(97)
00096-4
Carbone, E., and Lux, H. D. (1984). A low voltage-activated, fully inactivating Ca
channel in vertebrate sensory neurones. Nature 310, 501–502. doi: 10.1038/
310501a0
Cashin, M. F., and Moravek, V. (1927). The physiological action of cholesterol. Am.
J. Physiol. 82, 294–298. doi: 10.1152/ajplegacy.1927.82.2.294
Ceccarelli, I., Fiorenzani, P., Massafra, C., and Aloisi, A. M. (2003). Long-term
ovariectomy changes formalin-induced licking in female rats: the role of
estrogens. Reprod. Biol. Endocrinol. 1:24. doi: 10.1186/1477-7827-1-24
Chakrabarti, S., Liu, N. J., and Gintzler, A. R. (2010). Formation of mu/kappa-
opioid receptor heterodimer is sex-dependent and mediates female-specific
opioid analgesia. Proc. Natl. Acad. Sci. U.S.A. 107, 20115–20119. doi: 10.1073/
pnas.1009923107
Frontiers in Pharmacology | www.frontiersin.org 7 October 2018 | Volume 9 | Article 1127
fphar-09-01127 September 29, 2018 Time: 16:41 # 8
Joksimovic et al. Neurosteroids in Pain Management
Chen, S., Wang, J. M., Irwin, R. W., Yao, J., Liu, L., and Brinton, R. D. (2011).
Allopregnanolone promotes regeneration and reduces β-amyloid burden in
a preclinical model of Alzheimer’s disease. PLoS One 6:e24293. doi: 10.1371/
journal.pone.0024293
Compagnone, N. A., and Mellon, S. H. (2000). Neurosteroids: biosynthesis and
function of these novel neuromodulators. Front. Neuroendocrinol. 21, 1–56.
doi: 10.1006/frne.1999.0188
Coronel, M. F., Labombarda, F., De Nicola, A. F., and González, S. L. (2014).
Progesterone reduces the expression of spinal cyclooxygenase-2 and inducible
nitric oxide synthase and prevents allodynia in a rat model of central
neuropathic pain. Eur. J. Pain 18, 348–359. doi: 10.1002/j.1532-2149.2013.
00376.x
Coronel, M. F., Labombarda, F., Roig, P., Villar, M. J., De Nicola, A. F., and
González, S. L. (2011). Progesterone prevents nerve injury-induced allodynia
and spinal NMDA receptor upregulation in rats. Pain Med. 12, 1249–1261.
doi: 10.1111/j.1526-4637.2011.01178.x
Corpechot, C., Robel, P., Axelson, M., Sjovall, J., and Baulieu, E. E. (1981).
Characterization and measurement of dehydroepiandrosterone sulfate in rat
brain. Proc. Natl. Acad. Sci. U.S.A. 78, 4704–4707. doi: 10.1073/pnas.78.8.4704
Costigan, M., Scholz, J.,and Woolf, C. J. (2009). Neuropathic pain: a maladaptive
response of the nervous system to damage. Ann. Rev. Neurosci. 32, 1–32.
doi: 10.1146/annurev.neuro.051508.135531
Dableh, L. J., and Henry, J. L. (2011). Progesterone prevents development of
neuropathic pain in a rat model: timing and duration of treatment are critical.
J. Pain Res. 4, 91–101. doi: 10.2147/JPR.S17009
Dawson-Basoa, M., and Gintzler, A. R. (1997). Involvement of spinal cord δ δ opiate
receptors in the antinociception of gestation and its hormonal simulation. Brain
Res. 757, 37–42. doi: 10.1016/S0006-8993(97)00092-9
Dawson-Basoa, M., and Gintzler, A. R. (1998). Gestational and ovarian sex steroid
antinociception: synergy between spinal κ κ and δ δ opioid systems. Brain Res.
794, 61–67. doi: 10.1016/S0006-8993(98)00192-9
de la Puente, B., Nadal, X., Portillo-Salido, E., Sánchez-Arroyos, R., Ovalle, S.,
Palacios, G., et al. (2009). Sigma-1 receptors regulate activity-induced spinal
sensitization and neuropathic pain after peripheral nerve injury. Pain 145,
294–303. doi: 10.1016/j.pain.2009.05.013
Frye, C. A., Bock, B. C., and Kanarek, R. B. (1992). Hormonal milieu affects tailflick
latency in female rats and may be attenuated by access to sucrose. Physiol. Behav.
52, 699–706. doi: 10.1016/0031-9384(92)90400-V
Frye, C. A., Cuevas, C. A., and Kanarek, R. B. (1993). Diet and estrous cycle
influence pain sensitivity in rats. Pharmacol. Biochem. Behav. 45, 255–260.
doi: 10.1016/0091-3057(93)90116-B
Giatti, S., Pesaresi, M., Cavaletti, G., Bianchi, R., Carozzi, V., Lombardi, R.,
et al. (2009). Neuroprotective effects of a ligand of translocator protein-18kDa
(Ro5-4864) in experimental diabetic neuropathy. Neuroscience 164, 520–529.
doi: 10.1016/j.neuroscience.2009.08.005
Giatti, S., Romano, S., Pesaresi, M., Cermenati, G., Mitro, N., Caruso, D., et al.
(2015). Neuroactive steroids and the peripheral nervous system: an update.
Steroids 103, 23–30. doi: 10.1016/j.steroids.2015.03.014
Guennoun, R., Labombarda, F., Gonzalez Deniselle, M. C., Liere, P., De Nicola,
A. F., et al. (2015). Progesterone and allopregnanolone in the central nervous
system: response to injury and implication for neuroprotection. J. Steroid
Biochem. Mol. Biol. 146, 48–61. doi: 10.1016/j.jsbmb.2014.09.001
Guennoun, R., Meffre, D., Labombarda, F., Gonzalez, S. L., Deniselle, M. C. G.,
Stein, D. G., et al. (2008). The membrane-associated progesterone-binding
protein 25-Dx: expression, cellular localization and up-regulation after brain
and spinal cord injuries. Brain Res. Rev. 57, 493–505. doi: 10.1016/j.brainresrev.
2007.05.009
Herd, M. B., Belelli, D., and Lambert, J. J. (2007). Neurosteroid modulation of
synaptic and extrasynaptic GABAA receptors. Pharmacol. Ther. 116, 20–34.
doi: 10.1016/j.pharmthera.2007.03.007
Hernstadt, H., Wang, S., Lim, G., and Mao, J. (2009). Spinal translocator protein
(TSPO) modulates pain behavior in rats with CFA-induced monoarthritis.
Brain Res. 1286, 42–52. doi: 10.1016/j.brainres.2009.06.043
Hirose, M., Kuroda, Y., and Murata, E. (2016). NGF / TrkA signaling as a
therapeutic target for pain, pain pract. 16, 175–182.
Inoue, M., Oomura, Y., Yakushiji, T., Akaike, N. (1986). Intracellular calcium
ions decrease the affinity of the GABA receptor. Nature 324, 156–158.
doi: 10.1038/324156a0
Irwin, R. W., Solinsky, C. M., and Brinton, R. D. (2014). Frontiers in
therapeutic development of allopregnanolone for Alzheimer’s disease and other
neurological disorders. Front. Cell. Neurosci. 8:203. doi: 10.3389/fncel.2014.
00203
Jacus, M. O., Uebele, V. N., Renger, J. J., and Todorovic, S. M. (2012). Presynaptic
CaV3.2 channels regulate excitatory neurotransmission in nociceptive dorsal
horn neurons. J. Neurosci. 32, 9374–9382. doi: 10.1523/JNEUROSCI.0068-12.
2012
Jolivalt, C. G., Lee, C. A., Ramos, K. M., and Calcutt, N. A. (2008). Allodynia and
hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal
potassium-chloride co-transporters. Pain 140, 48–57. doi: 10.1016/j.pain.2008.
07.005
Kibaly, C., Meyer, L., Patte-Mensah, C., and Mensah-Nyagan, A. G. (2007).
Biochemical and functional evidence for the control of pain mechanisms by
dehydroepiandrosterone endogenously synthesized in the spinal cord. FASEB J.
22, 93–104. doi: 10.1096/fj.07-8930com
Kibaly, C., Patte-Mensah, C., and Mensah-Nyagan, A. G. (2005). Molecular and
neurochemical evidence for the biosynthesis of dehydroepiandrosterone in the
adult rat spinal cord. J. Neurochem. 93, 1220–1230. doi: 10.1111/j.1471-4159.
2005.03113.x
Kim, H. W., Roh, D. H., Yoon, S. Y., Seo, H. S., Kwon, Y. B., Han, H. J., et al. (2008).
Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via
PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice. Br. J.
Pharmacol. 154, 1125–1134. doi: 10.1038/bjp.2008.159
Kim, M. J., Shin, H. J., Won, K. A., Yang, K. Y., Ju, J. S., Park, Y. Y., et al. (2012).
Progesterone produces antinociceptive and neuroprotective effects in rats with
microinjected lysophosphatidic acid in the trigeminal nerve root. Mol. Pain
8:16. doi: 10.1186/1744-8069-8-16
Kuba, T., and Quinones-Jenab, V. (2005). The role of female gonadal hormones
in behavioral sex differences in persistent and chronic pain: clinical versus
preclinical studies. Brain Res. Bull. 66, 179–188. doi: 10.1016/j.brainresbull.
2005.05.009
Labombarda, F., Meffre, D., Delespierre, B., Krivokapic-Blondiaux, S., Chastre, A.,
Thomas, P., et al. (2010). Membrane progesterone receptors localization in the
mouse spinal cord. Neuroscience 166, 94–106. doi: 10.1016/j.neuroscience.2009.
12.012
Lambert, J. J., Belelli, D., Harney, S. C., Peters, J. A., and Frenguelli, B. G. (2001).
Modulation of native and recombinant GABAA receptors by endogenous and
synthetic neuroactive steroids. Brain Res. Brain Res. Rev. 37, 68–80. doi: 10.
1016/S0165-0173(01)00124-2
Latham, J. R., Pathirathna, S., Jagodic, M. M., Choe, W. J., Levin, M. E., Nelson,
M. T., Lee, W. Y., Krishnan, K., Covey, D. F., Todorovic, S. M., Jevtovic-
Todorovic, V. (2009). Selective T-type calcium channel blockade alleviates
hyperalgesia in ob/ob mice. Diabetes 58, 2656–2665. doi: 10.2337/db08-1763
Lazaridis, I., Charalampopoulos, I., Alexaki, V. I., Avlonitis, N., Pediaditakis, I.,
Efstathopoulos, P., et al. (2011). Neurosteroid dehydroepiandrosterone
interacts with nerve growth factor (NGF) receptors, preventing neuronal
apoptosis. PLoS Biol. 9:e1001051. doi: 10.1371/journal.pbio.1001051
Leonelli, E., Bianchi, R., Cavaletti, G., Caruso, D., Crippa, D., Garcia-Segura, L. M.,
et al. (2007). Progesterone and its derivatives are neuroprotective agents in
experimental diabetic neuropathy: a multimodal analysis. Neuroscience 144,
1293–1304. doi: 10.1016/j.neuroscience.2006.11.014
Llano, I., Leresche, N., and Marty, A. (1991). Calcium entry increases the sensitivity
of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic
currents. Neuron 6, 565–574. doi: 10.1016/0896-6273(91)90059-9
Maurice, T., Grégoire, C., and Espallergues, J. (2006). Neuro(active)steroids actions
at the neuromodulatory sigma1(σ1) receptor: biochemical and physiological
evidences, consequences in neuroprotection. Pharmacol. Biochem. Behav. 84,
581–597. doi: 10.1016/j.pbb.2006.07.009
Mavlyutov, T. A., Duellman, T., Kim, H. T., Epstein, M. L., Leese, C., Davletov,
B. A., et al. (2016). Sigma-1 receptor expression in the dorsal root ganglion:
reexamination using a highly specific antibody. Neuroscience 331, 148–157.
doi: 10.1016/j.neuroscience.2016.06.030
Melcangi, R. C., Garcia-Segura, L. M., and Mensah-Nyagan, A. G. (2008).
Neuroactive steroids: state of the art and new perspectives. Cell. Mol. Life Sci.
65, 777–797. doi: 10.1007/s00018-007-7403-5
Melcangi, R. C., Giatti, S., Calabrese, D., Pesaresi, M., Cermenati, G., Mitro, N.,
et al. (2014). Levels and actions of progesterone and its metabolites in
Frontiers in Pharmacology | www.frontiersin.org 8 October 2018 | Volume 9 | Article 1127
fphar-09-01127 September 29, 2018 Time: 16:41 # 9
Joksimovic et al. Neurosteroids in Pain Management
the nervous system during physiological and pathological conditions. Prog.
Neurobiol. 113, 56–69. doi: 10.1016/j.pneurobio.2013.07.006
Mellon, S. H., and Griffin, L. D. (2002). Neurosteroids: biochemistry and clinical
significance. Trends Endocrinol. Metab. 13, 35–43. doi: 10.1016/S1043-2760(01)
00503-3
Mensah-Nyagan, A. G., Do-Rego, J. L., Beaujean, D., Luu-The, V., Pelletier, G.,
and Vaudry, H. (1999). Neurosteroids: expression of steroidogenic enzymes and
regulation of steroid biosynthesis in the the central nervous system. Pharmacol.
Rev. 51, 63—81
Mensah-Nyagan, A. G., Kibaly, C., Schaeffer, V., Venard, C., Meyer, L., and Patte-
Mensah, C. (2008). Endogenous steroid production in the spinal cord and
potential involvement in neuropathic pain modulation. J. Steroid Biochem. Mol.
Biol. 109, 286–293. doi: 10.1016/j.jsbmb.2008.03.002
Mensah-Nyagan, A. G., Meyer, L., Schaeffer, V., Kibaly, C., and Patte-Mensah, C.
(2009). Evidence for a key role of steroids in the modulation of pain.
Psychoneuroendocrinology 34(Suppl. 1), S169–S177. doi: 10.1016/j.psyneuen.
2009.06.004
Meyer, L., Patte-Mensah, C., Taleb, O., and Mensah-Nyagan, A. G. (2010).
Cellular and functional evidence for a protective action of neurosteroids against
vincristine chemotherapy-induced painful neuropathy. Cell. Mol. Life Sci. 67,
3017–3034. doi: 10.1007/s00018-010-0372-0
Meyer, L., Patte-Mensah, C., Taleb, O., and Mensah-Nyagan, A. G. (2011).
Allopregnanolone prevents and suppresses oxaliplatin-evoked painful
neuropathy: multi-parametric assessment and direct evidence. Pain 152,
170–181. doi: 10.1016/j.pain.2010.10.015
Mihalek, R. M., Banerjee, P. K., Korpi, E. R., Quinlan, J. J., Firestone,
L. L., Mi, Z. P., et al. (1999). Attenuated sensitivity to neuroactive
steroids in gamma -aminobutyrate type A receptor delta subunit knockout
mice. Proc. Natl. Acad. Sci. U.S.A. 96, 12905–12910. doi: 10.1073/pnas.
96.22.12905
Millan, M. J. (1999). The induction of pain: an integrative review. Prog. Neurobiol.
57, 1–164. doi: 10.1016/S0301-0082(98)00048-3
Millan, M. J. (2002). Descending control of pain. Prog. Neurobiol. 66, 355–474.
doi: 10.1016/S0301-0082(02)00009-6
Mitro, N., Cermenati, G., Giatti, S., Abbiati, F., Pesaresi, M., Calabrese, D.,
et al. (2012). LXR and TSPO as new therapeutic targets to increase the levels
of neuroactive steroids in the central nervous system of diabetic animals.
Neurochem. Int. 60, 616–621. doi: 10.1016/j.neuint.2012.02.025
Monnet, F. P., and Maurice, T. (2006). The sigma 1 protein as a target for
the non-genomic effects of neuro(active)steroids: molecular, physiological,
and behavioral aspects. J. Pharmacol. Sci. 100, 93–118. doi: 10.1254/jphs.
CR0050032
Obradovic, A. L., Scarpa, J., Osuru, H. P., Weaver, J. L., Park, J. Y., Pathirathna, S.,
et al. (2015). Silencing the α2 subunit of γ-aminobutyric acid type a
receptors in rat dorsal root ganglia reveals its major role in antinociception
posttraumatic nerve injury Anesthesiology 123, 654–667. doi: 10.1097/ALN.
0000000000000767
Ortíz-Rentería, M., Juárez-Contreras, R., González-Ramírez, R., Islas, L. D., Sierra-
Ramírez, F., Llorente, I., et al. (2018). TRPV1 channels and the progesterone
receptor Sig-1R interact to regulate pain. Proc. Natl. Acad. Sci. U.S.A. 115,
E1657–E1666. doi: 10.1073/pnas.1715972115
Park, C., Kim, J. H., Yoon, B. E., Choi, E. J., Lee, C. J., and Shin, H. S. (2010). T-type
channels control the opioidergic descending analgesia at the low threshold-
spiking GABAergic neurons in the periaqueductal gray. Proc. Natl. Acad. Sci.
U.S.A. 107, 14857–14862. doi: 10.1073/pnas.1009532107
Pathirathna, S., Brimelow, B. C., Jagodic, M. M., Krishnan, K., Jiang, X., Zorumski,
C. F., et al. (2005a). New evidence that both T-type calcium channels and
GABAAchannels are responsible for the potent peripheral analgesic effects of
5α-reduced neuroactive steroids. Pain 114, 429–443. doi: 10.1016/j.pain.2005.
01.009
Pathirathna, S., Todorovic, S. M., Covey, D. F., and Jevtovic-Todorovic, V.
(2005b). 5α-reduced neuroactive steroids alleviate thermal and mechanical
hyperalgesia in rats with neuropathic pain. Pain 117, 326–339.
doi: 10.1016/j.pain.2005.06.019
Patte-Mensah, C., Kappes, V., Freund-Mercier, M. J., Tsutsui, K., and Mensah-
Nyagan, A. G. (2003). Cellular distribution and bioactivity of the key
steroidogenic enzyme, cytochrome P450side chain cleavage, in sensory neural
pathways. J. Neurochem. 86, 1233–1246. doi: 10.1046/j.1471-4159.2003.01935.x
Patte-Mensah, C., Kibaly, C., Boudard, D., Schaeffer, V., Begle, A., Saredi, S.,
et al. (2006). Neurogenic pain and steroid synthesis in the spinal cord. J. Mol.
Neurosci. 28, 17–32. doi: 10.1385/JMN/28
Patte-Mensah, C., Kibaly, C., and Mensah-Nyagan, A. G. (2005). Substance P
inhibits progesterone conversion to neuroactive metabolites in spinal sensory
circuit: a potential component of nociception. Proc. Natl. Acad. Sci. U.S.A. 102,
9044–9049. doi: 10.1073/pnas.0502968102
Patte-Mensah, C., Penning, T. M., Mensah-Nyagan, A. G. (2004). Anatomical
and cellular localization of neuroactive 5 alpha/3 alpha-reduced steroid-
synthesizing enzymes in the spinal cord. J. Comp. Neurol. 477, 286–299.
PubMed. doi: 10.1002/cne.20251
Paul, S. M., and Purdy, R. H. (1992). Neuroactive steroids. FASEB J. 6, 2311–2322.
doi: 10.1096/fasebj.6.6.1347506
Pediaditakis, I., Efstathopoulos, P., Prousis, K. C., Zervou, M., Arévalo, J. C.,
Alexaki, V. I., et al. (2016). Selective and differential interactions of BNN27,
a novel C17-spiroepoxy steroid derivative, with TrkA receptors, regulating
neuronal survival and differentiation. Neuropharmacology 111, 266–282. doi:
10.1016/j.neuropharm.2016.09.007
Riley, J. L. III, Robinson, M. E., Wise, E. A., Myers, C. D., and Fillingim, R. B.
(1998). Sex differences in the perception of noxious experimental stimuli: a
meta-analysis. Pain 74, 181–187. doi: 10.1016/S0304-3959(97)00199-1
Roglio, I., Bianchi, R., Gotti, S., Scurati, S., Giatti, S., Pesaresi, M., et al.
(2008). Neuroprotective effects of dihydroprogesterone and progesterone in
an experimental model of nerve crush injury. Neuroscience 155, 673–685.
doi: 10.1016/j.neuroscience.2008.06.034
Rose, K. E., Lunardi, N., Boscolo, A., Dong, X., Erisir, A., Jevtovic-Todorovic, V.,
et al. (2013). Immunohistological demonstration of CaV3.2 T-type voltage-
gated calcium channel expression in soma of dorsal root ganglion neurons and
peripheral axons of rat and mouse. Neuroscience 250, 263–274. doi: 10.1016/j.
neuroscience.2013.07.005
Rougé-Pont, F., Mayo, W., Marinelli, M., Gingras, M., Le Moal, M., et al.
(2002). The neurosteroid allopregnanolone increases dopamine release and
dopaminergic response to morphine in the rat nucleus accumbens. Eur. J.
Neurosci. 16, 169–173. doi: 10.1046/j.1460-9568.2002.02084.x
Schumacher, M., Mattern, C., Ghoumari, A., Oudinet, J. P., Liere, P.,
Labombarda, F., et al. (2014). Revisiting the roles of progesterone and
allopregnanolone in the nervous system: resurgence of the progesterone
receptors. Prog. Neurobiol. 113, 6–39. doi: 10.1016/j.pneurobio.2013.09.004
Schumacher, M., Hussain, R., Gago, N., Oudinet, J. P., Mattern, C., and Ghoumari,
A. M. (2012). Progesterone synthesis in the nervous system: implications for
myelination and myelin repair. Front. Neurosci. 6:10. doi: 10.3389/fnins.2012.
00010
Stell, B. M., Brickley, S. G., Tang, C. Y., Farrant, M., Mody, I. (2003). Neuroactive
steroids reduce neuronal excitability by selectively enhancing tonic inhibition
mediated by delta subunit-containing GABAA receptors. Proc. Natl. Acad. Sci.
U.S.A. 100, 14439–14444. doi: 10.1073/pnas.2435457100
Todorovic, S. M., Jevtovic-Todorovic, V., Meyenburg, A., Mennerick, S., Perez-
Reyes, E., Romano, C., et al. (2001). Redox modulation of T-Type calcium
channels in rat peripheral nociceptors. Neuron 31, 75–85. doi: 10.1016/S0896-
6273(01)00338-5
Todorovic, S. M., Prakriya, M., Nakashima, Y. M., Nilsson, K. R., Han, M.,
Zorumski, C. F., et al. (1998). Enantioselective blockade of t-type Ca2
+ current in adult rat sensory neurons by a steroid that lacks gamma-
aminobutyric acid-modulatory activity. Mol. Pharmacol. 54, 918–927.
doi: 10.1124/mol.54.5.918
Todorovic, S. M., Pathirathna, S., Brimelow, B. C., Jagodic, M. M., Ko, S. H.,
Jiang, X., et al. (2004). 5beta-reduced neuroactive steroids are novel voltage-
dependent blockers of T-type Ca2 + channels in rat sensory neurons in vitro
and potent peripheral analgesics in vivo. Mol. Pharmacol. 66, 1223–1235.
doi: 10.1124/mol.104.002402
Wang, M., Singh, C., Liu, L., Irwin, R. W., Chen, S., Chung, E. J., et al. (2010).
Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of
Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 107, 6498–6503. doi: 10.1073/
pnas.1006236107.
Xiao, H. S., Huang, Q. H., Zhang, F. X., Bao, L., Lu, Y. J., Guo, C., et al. (2002).
Identification of gene expression profile of dorsal root ganglion in the rat
peripheral axotomy model of neuropathic pain. Proc. Natl. Acad. Sci. U.S.A. 99,
8360–8365. doi: 10.1073/pnas.122231899
Frontiers in Pharmacology | www.frontiersin.org 9 October 2018 | Volume 9 | Article 1127
fphar-09-01127 September 29, 2018 Time: 16:41 # 10
Joksimovic et al. Neurosteroids in Pain Management
Xiong, B. J., Xu, Y., Jin, G. L., Liu, M., Yang, J., and Yu, C. X. (2017). Analgesic
effects and pharmacologic mechanisms of the Gelsemium alkaloid koumine on
a rat model of postoperative pain. Sci. Rep. 7:14269. doi: 10.1038/s41598-017-
14714-0
Yang, L. A., Zhang, F. X., Huang, F., Lu, Y. J., Li, G. D., Bao, L., et al.
(2004). Peripheral nerve injury induces trans-synaptic modification
of channels, receptors and signal pathways in rat dorsal spinal
cord. Eur. J. Neurosci. 19, 871–883. doi: 10.1111/j.1460-9568.
2004.03121.x
Yoon, S. Y., Roh, D. H., Seo, H. S., Kang, S. Y., Moon, J. Y., Song, S.,
et al. (2010). An increase in spinal dehydroepiandrosterone sulfate
(DHEAS) enhances NMDA-induced pain via phosphorylation of
the NR1 subunit in mice: involvement of the sigma-1 receptor.
Neuropharmacology 59, 460–467. doi: 10.1016/j.neuropharm.
2010.06.007
Zeilhofer, H. U., Wildner, H., and Yevenes, G. E. (2013). Fast synaptic inhibition
in spinal sensory processing and pain control. Physiol. Rev. 92, 193–235. doi:
10.1152/physrev.00043.2010
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Joksimovic, Covey, Jevtovic-Todorovic and Todorovic. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 10 October 2018 | Volume 9 | Article 1127
